You are here
GSK shutting down Biopolis neural unit
IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org